ArticleEClinicalMedicine2020

Assessing the risk-benefit profile of ramucirumab in patients with advanced solid tumors: A meta-analysis of randomized controlled trials.

Sophie Marie Anne Effing et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.